TRDA ENTRADA THERAPEUTICS INC

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular and Bone Corporate Panel at the Cowen 43rd Annual Health Care Conference. The panel will be held on Wednesday, March 8, 2023 at 2:10 p.m. Eastern Time in Boston, MA.

A live webcast will be available on the Investor Relations section of the Company’s website at . A replay will be available on the Entrada website for 90 days following the event.

About Entrada Therapeutics

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™)-therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for the potential treatment of people living with Duchenne who are exon 44 and 45 skipping amenable, respectively, as well as ENTR-701 targeting myotonic dystrophy type 1 (DM1).

For more information about Entrada, please visit our website, , and follow us on  and .

Investor and Media Contact

Karla MacDonald

Chief Corporate Affairs Officer



EN
27/02/2023

Underlying

TRDAENTRADA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENTRADA THERAPEUTICS INC

 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board o...

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. “We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan’s deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne progr...

7h / 29m 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing ...

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units (“RSUs”) to six newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of June 1, 2025. The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment ...

21h / 59m 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Receives Authorization in the European Union to I...

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping – Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the Health Authorities an...

May 28, 2025 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Entrada Therapeutics Reports First Quarter 2025 Financial Results – Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 and ELEVATE-45-201 in Q2 and Q3 2025, respectively – – Cash runway expected into Q2 2027 with $383 million in cash, cash equivalents and marketable securities as of March 31, 2025 – BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) tod...

May 8, 2025 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Receives Authorization in the United Kingdom to I...

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping – Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing –  – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada T...

March 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch